View Entire Collection
By Clinical Topic
By State Requirement
Diabetes – Summer 2012
Future of Nursing Initiative
Heart Failure - Fall 2011
Influenza - Winter 2011
Nursing Ethics - Fall 2011
Trauma - Fall 2010
Traumatic Brain Injury - Fall 2010
Fluids & Electrolytes
FRIDAY, April 9 (HealthDay News) -- A single chlamydia screening does not prevent most cases of pelvic inflammatory disease over 12 months, and most cases that do occur are in women who were negative for chlamydia at baseline, according to a study published online April 8 in BMJ.
Pippa Oakeshott, M.D., of the University of London, and colleagues recruited 2,529 sexually active female students (mean age, 21 years). The women provided vaginal swabs to screen for chlamydial infection, and then were randomized to either immediate testing and treatment for chlamydia or storage and analysis after a year.
The researchers found that the incidence of pelvic inflammatory disease was 1.3 percent in screened women compared with 1.9 percent in controls. In addition, 9.5 percent of control women who tested positive for chlamydial infection at baseline developed pelvic inflammatory disease over 12 months compared to 1.6 percent of screened women. However, most occurrences of pelvic inflammatory disease (79 percent) occurred in women who tested negative for chlamydial infection at baseline.
"Although some evidence suggests that screening for chlamydia reduces rates of pelvic inflammatory disease, especially in women with chlamydial infection at baseline, the effectiveness of a single chlamydia test in preventing pelvic inflammatory disease over 12 months may have been overestimated," the authors write.
Gen-Probe provided transcription mediated amplification sample collecting kits for the study.
Sign up for our free enewsletters to stay up-to-date in your area of practice - or take a look at an archive of prior issues
Join our CESaver program to earn up to 100 contact hours for only $34.95
Explore a world of online resources
Back to Top